Weight loss drug biosimilar market set to reach $3.88 billion by 2030

The weight loss drug biosimilar market is projected to nearly triple by 2030 as obesity rates climb, patent expirations open the door for lower-cost alternatives, and healthcare systems look for ways to contain spending. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - The weight loss drug biosimilar market is moving from a niche opportunity to a fast-scaling part of the obesity-treatment landscape. - Rising demand for lower-cost alternatives could broaden access to metabolic therapies as obesity rates keep climbing worldwide. - The market is also a test case for how patent expirations, regulatory pathways and payer pressure can reshape biologic drug competition.

What happened: - The Business Research Company projected the global weight loss drug biosimilar market will grow from $1.21 billion in 2025 to $1.53 billion in 2026. - The firm said the market is expected to reach $3.88 billion by 2030. - The report estimated a CAGR of 26.6% for 2025-2026 and 26.2% for 2026-2030. - The report was published Sept. 24, 2026. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Obesity growth is the main demand driver, with higher rates linked to diabetes, heart disease and hypertension. - The report ties rising obesity to more consumption of high-calorie processed foods and less physical activity. - Weight loss drug biosimilars are designed to closely replicate branded therapies used for weight management. - The products are intended to match originator drugs in safety, quality, efficacy and clinical performance after patent or exclusivity periods end. - The biosimilars are produced using living cells and biotech methods. - GLP-1 receptor activity is a key target for the category. - Patent expirations on original biologic drugs are expected to increase competition and lower costs. - Regulatory harmonization is making interchangeability approvals easier. - Better cold chain logistics are supporting distribution of temperature-sensitive injectable drugs. - Payers and formularies are tightening access to branded weight loss biologics, which makes biosimilars more attractive. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology and future trend analysis, and updated graphics and tables.

Between the lines: - The market outlook suggests obesity treatment is shifting from branded biologic dominance toward price-sensitive competition. - The fastest growth is likely to come from markets where healthcare access is expanding and biosimilar adoption is still early. - The report points to a broader industry pattern: once key biologics lose exclusivity, cost containment and formulary pressure can quickly accelerate biosimilar uptake.

What's next: - More weight loss biologics are likely to face biosimilar competition as patents expire. - Biosimilar developers will likely keep expanding pipelines to capture the projected growth window through 2030. - Adoption should increase where healthcare systems prioritize affordability and long-term metabolic disease management. - The Business Research Company is directing readers to a free sample of the market report and the full market report.

The bottom line: - Weight loss drug biosimilars are positioned for rapid growth as obesity rises, branded biologics lose exclusivity and healthcare systems push for cheaper treatment options.